Jasper Therapeutics Inc (JSPRW)
$0.01
$0.00
(-0.82%)
As on 28-Jul-2026 09:34EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
5 Years Aggregate
CFO
$-151.84 Mln
EBITDA
$-186.70 Mln
Net Profit
$-149.28 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Jasper Therapeutics Inc (JSPRW)
| -69.8 | -40.7 | -22.9 | -87.9 | -52.1 | -- | -- |
|
BSE Sensex*
| -8.0 | 1.6 | 0.6 | -4.2 | 5.6 | 8.2 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Jasper Therapeutics Inc (JSPRW)
| -80.8 | 160.6 | 166.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Jasper Therapeutics Inc (JSPRW)
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed... to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California. Read more
-
President, CEO & Director
Mr. Ronald A. Martell
-
President, CEO & Director
Mr. Ronald A. Martell
-
Headquarters
Redwood City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Jasper Therapeutics Inc (JSPRW)
What is the current share price of Jasper Therapeutics Inc (JSPRW) Today?
The share price of Jasper Therapeutics Inc (JSPRW) is $0.01 (NASDAQ) as of 28-Jul-2026 09:34 EDT. Jasper Therapeutics Inc (JSPRW) has given a return of -52.1% in the last 3 years.
What is the current PB & PE ratio of Jasper Therapeutics Inc (JSPRW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.01
|
0.15
|
|
2024
|
-0.04
|
0.05
|
|
2023
|
-0.01
|
0.01
|
|
2022
|
0.00
|
0.00
|
|
2021
|
-0.04
|
0.02
|
What is the 52 Week High and Low of Jasper Therapeutics Inc (JSPRW)?
The 52-week high and low of Jasper Therapeutics Inc (JSPRW) are Rs 0.15 and Rs 0.01 as of 31-Jul-2026.
What is the market cap of Jasper Therapeutics Inc (JSPRW)?
Jasper Therapeutics Inc (JSPRW) has a market capitalisation of -- as on 24-Jul-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Jasper Therapeutics Inc (JSPRW)?
Before investing in Jasper Therapeutics Inc (JSPRW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.